Marisa Palmeri

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

ESMO Open · 2022 · First of 18 authors · 289 citations

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology · 2021 · 214 citations